Agios Reports Q1 Revenue of $20.75M, Beating Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Should l Buy AGIO?
Reports Q1 revenue $20.75M, consensus $13.65M. Reports Q1 Cash, cash equivalents, and marketable securities $1.045B. "Our Q1 performance reflects strong execution and significant progress against our 2026 strategic objectives," said Brian Goff, CEO, Agios. "The solid early momentum of our U.S. commercial launch of AQVESME in thalassemia highlights both the medicine's clinical value and strong community reception. Additionally, following collaborative engagement with the FDA, we now plan to submit our mitapivat sNDA for sickle cell disease under the U.S. accelerated approval pathway in the second quarter. 2026 marks an important growth inflection point for Agios as we continue to build a sustainable rare disease company that is rooted in hematology and focused on delivering differentiated medicines that create meaningful long-term value for patients and shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 27.790
Low
25.00
Averages
36.14
High
62.00
Current: 27.790
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agios Pharmaceuticals Shares Rise 11.2% Following Strong Earnings Report
- Stock Surge: Agios Pharmaceuticals saw an 11.2% increase in shares this week, marking a positive turnaround for the year, reflecting market confidence in the company's future, particularly following the successful launch of Aqvesme.
- Significant Sales Growth: Aqvesme's sales reached $20.7 million in Q1 2026, a substantial increase from $8.7 million in the same quarter of 2025, which not only boosts overall revenue but also establishes a solid foundation for future market demand.
- New Drug Progress: Management confirmed alignment with the FDA, expecting to file for accelerated approval of mitapivat for sickle cell disease in Q2 2026, despite facing competition from Novo Nordisk, indicating strong market potential.
- Optimistic Future Outlook: Management is optimistic about the Phase 2 trial results for tebapivat, expected in the first half of 2026 for MDS and the second half for SCD, which will provide new momentum for the company's growth trajectory.
See More
Agios Pharmaceuticals Shares Surge 13.11% After Earnings Report
- Strong Earnings Report: Agios Pharmaceuticals reported a significant revenue increase from $8.7 million to $20.7 million year-over-year, demonstrating robust market performance for its new drug Aqvesme, highlighting the company's competitiveness in the anemia treatment sector.
- Widening Net Loss: Despite revenue growth, Agios' net loss expanded from $89 million to over $99 million, with a loss per share of $1.69, which, while exceeding analyst expectations, indicates ongoing investment in research and development.
- FDA Application Plans: Agios intends to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat to treat adult sickle cell disease, which, if approved, could further expand its market potential and enhance future revenue streams.
- Positive Market Reaction: Following a strong U.S. launch of Aqvesme, Agios' stock surged over 13% during trading, reflecting investor confidence in the company's future growth and strong market recognition of its products.
See More
Agios Pharmaceuticals Reports $21 Million Revenue in Q1
- Significant Revenue Growth: Agios Pharmaceuticals reported a revenue of $20.7 million in Q1, a 138% increase from $8.7 million in the same quarter last year, indicating strong market acceptance and sales potential for its new drug Aqvesme.
- FDA Approval for New Drug: Mitapivat has received FDA approval for the treatment of two blood disorders, further solidifying Agios's market position in the hematology sector and laying the groundwork for future revenue growth.
- Deepening Net Loss: Despite the revenue increase, Agios's net loss deepened to over $99 million in Q1, translating to a loss of $1.69 per share, which exceeded analyst expectations, yet the company remains optimistic about its future prospects.
- Future Development Plans: Agios plans to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat's use in treating adult sickle cell disease, which, if successful, will further expand its market share and product line.
See More
Agios Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Agios Pharmaceuticals reported net revenues of $20.7 million in Q1 2026, reflecting a 138% year-over-year increase, indicating strong market performance and growth potential, particularly driven by the new product AQVESME.
- Increase in AQVESME Prescriptions: As of March 31, the number of prescriptions for AQVESME reached 242, demonstrating early market acceptance in thalassemia treatment, which is expected to be a key driver of future growth for the company.
- sNDA Submission Plans: The company plans to submit an sNDA for mitapivat in sickle cell disease to the FDA in Q2, aiming for accelerated approval, a strategic move that will help expand market share and enhance competitive positioning.
- Cost Control Strategy: The CFO indicated that operating expenses for 2026 are expected to remain flat compared to 2025, demonstrating the company's commitment to strict cost management while expanding its business to ensure financial health and sustainable growth.
See More
Agios Pharmaceuticals Q1 2026 Earnings Highlights
- Earnings Beat: Agios Pharmaceuticals reported a Q1 2026 GAAP EPS of -$1.69, beating estimates by $0.11, indicating an improvement in financial performance.
- Significant Revenue Growth: The company achieved revenues of $20.75 million, a 137.7% year-over-year increase, surpassing market expectations by $7.41 million, reflecting strong product sales and market demand.
- Cash Reserves Update: As of March 31, 2026, Agios reported cash, cash equivalents, and marketable securities totaling $1.0 billion, down from $1.2 billion as of December 31, 2025, highlighting expenditures in investments and operations.
- Future Outlook: Agios anticipates that its cash reserves will support the U.S. launch of AQVESME for thalassemia, prepare for mitapivat in sickle cell disease, advance clinical programs, and expand its pipeline, demonstrating confidence in future growth.
See More
Agios Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Updates
- Significant Revenue Growth: In Q1 2026, Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million, a remarkable 137% increase from $8.7 million in Q1 2025, indicating strong performance in the rare disease market.
- Successful U.S. Launch: As of March 31, 2026, 242 prescriptions for AQVESME in thalassemia were written, reflecting active engagement from both physicians and patients, which further solidifies Agios's market position in this therapeutic area.
- Accelerated R&D Progress: The company plans to submit a supplemental New Drug Application (sNDA) for Mitapivat in sickle cell disease in Q2 2026, which will expedite its product launch in the U.S. market to address unmet medical needs.
- Strong Financial Position: As of March 31, 2026, Agios reported $1.0 billion in cash and cash equivalents, providing sufficient resources to support its commercialization strategies and R&D activities, ensuring ongoing growth and innovation in the rare disease sector.
See More
Agios Pharmaceuticals Shares Rise 11.2% Following Strong Earnings Report
- Stock Surge: Agios Pharmaceuticals saw an 11.2% increase in shares this week, marking a positive turnaround for the year, reflecting market confidence in the company's future, particularly following the successful launch of Aqvesme.
- Significant Sales Growth: Aqvesme's sales reached $20.7 million in Q1 2026, a substantial increase from $8.7 million in the same quarter of 2025, which not only boosts overall revenue but also establishes a solid foundation for future market demand.
- New Drug Progress: Management confirmed alignment with the FDA, expecting to file for accelerated approval of mitapivat for sickle cell disease in Q2 2026, despite facing competition from Novo Nordisk, indicating strong market potential.
- Optimistic Future Outlook: Management is optimistic about the Phase 2 trial results for tebapivat, expected in the first half of 2026 for MDS and the second half for SCD, which will provide new momentum for the company's growth trajectory.
See More
Agios Pharmaceuticals Shares Surge 13.11% After Earnings Report
- Strong Earnings Report: Agios Pharmaceuticals reported a significant revenue increase from $8.7 million to $20.7 million year-over-year, demonstrating robust market performance for its new drug Aqvesme, highlighting the company's competitiveness in the anemia treatment sector.
- Widening Net Loss: Despite revenue growth, Agios' net loss expanded from $89 million to over $99 million, with a loss per share of $1.69, which, while exceeding analyst expectations, indicates ongoing investment in research and development.
- FDA Application Plans: Agios intends to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat to treat adult sickle cell disease, which, if approved, could further expand its market potential and enhance future revenue streams.
- Positive Market Reaction: Following a strong U.S. launch of Aqvesme, Agios' stock surged over 13% during trading, reflecting investor confidence in the company's future growth and strong market recognition of its products.
See More
Agios Pharmaceuticals Reports $21 Million Revenue in Q1
- Significant Revenue Growth: Agios Pharmaceuticals reported a revenue of $20.7 million in Q1, a 138% increase from $8.7 million in the same quarter last year, indicating strong market acceptance and sales potential for its new drug Aqvesme.
- FDA Approval for New Drug: Mitapivat has received FDA approval for the treatment of two blood disorders, further solidifying Agios's market position in the hematology sector and laying the groundwork for future revenue growth.
- Deepening Net Loss: Despite the revenue increase, Agios's net loss deepened to over $99 million in Q1, translating to a loss of $1.69 per share, which exceeded analyst expectations, yet the company remains optimistic about its future prospects.
- Future Development Plans: Agios plans to submit a supplemental New Drug Application (sNDA) to the FDA this quarter for mitapivat's use in treating adult sickle cell disease, which, if successful, will further expand its market share and product line.
See More
Agios Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Agios Pharmaceuticals reported net revenues of $20.7 million in Q1 2026, reflecting a 138% year-over-year increase, indicating strong market performance and growth potential, particularly driven by the new product AQVESME.
- Increase in AQVESME Prescriptions: As of March 31, the number of prescriptions for AQVESME reached 242, demonstrating early market acceptance in thalassemia treatment, which is expected to be a key driver of future growth for the company.
- sNDA Submission Plans: The company plans to submit an sNDA for mitapivat in sickle cell disease to the FDA in Q2, aiming for accelerated approval, a strategic move that will help expand market share and enhance competitive positioning.
- Cost Control Strategy: The CFO indicated that operating expenses for 2026 are expected to remain flat compared to 2025, demonstrating the company's commitment to strict cost management while expanding its business to ensure financial health and sustainable growth.
See More
Agios Pharmaceuticals Q1 2026 Earnings Highlights
- Earnings Beat: Agios Pharmaceuticals reported a Q1 2026 GAAP EPS of -$1.69, beating estimates by $0.11, indicating an improvement in financial performance.
- Significant Revenue Growth: The company achieved revenues of $20.75 million, a 137.7% year-over-year increase, surpassing market expectations by $7.41 million, reflecting strong product sales and market demand.
- Cash Reserves Update: As of March 31, 2026, Agios reported cash, cash equivalents, and marketable securities totaling $1.0 billion, down from $1.2 billion as of December 31, 2025, highlighting expenditures in investments and operations.
- Future Outlook: Agios anticipates that its cash reserves will support the U.S. launch of AQVESME for thalassemia, prepare for mitapivat in sickle cell disease, advance clinical programs, and expand its pipeline, demonstrating confidence in future growth.
See More
Agios Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Updates
- Significant Revenue Growth: In Q1 2026, Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million, a remarkable 137% increase from $8.7 million in Q1 2025, indicating strong performance in the rare disease market.
- Successful U.S. Launch: As of March 31, 2026, 242 prescriptions for AQVESME in thalassemia were written, reflecting active engagement from both physicians and patients, which further solidifies Agios's market position in this therapeutic area.
- Accelerated R&D Progress: The company plans to submit a supplemental New Drug Application (sNDA) for Mitapivat in sickle cell disease in Q2 2026, which will expedite its product launch in the U.S. market to address unmet medical needs.
- Strong Financial Position: As of March 31, 2026, Agios reported $1.0 billion in cash and cash equivalents, providing sufficient resources to support its commercialization strategies and R&D activities, ensuring ongoing growth and innovation in the rare disease sector.
See More
